The American Heart Association outlined several considerations for the management of pregnant women with CVD or CVD-related conditions.
The FDA has issued a statement regarding the use of nonsteroidal anti-inflammatory drugs (NSAIDS) in patients with coronavirus disease 2019 (COVID-19).
On March 6, 2020, the American College of Cardiology issued COVID-19 clinical guidance for the cardiovascular care team.
In patients coinfected with HIV and HCV, eradication of HCV had no effect on markers of preclinical atherosclerosis and biomarkers of inflammation and endothelial dysfunction.
The FDA has granted Breakthrough Therapy designation to apabetalone in combination with standard of care therapy for the secondary prevention of MACE in patients with T2Dm and recent ACS.
Lower use of low-dose aspirin for the primary prevention of cardiovascular disease (CVD) in blacks vs whites may partly account for racial discrepancies in the incidence of ischemic cardiac death.